- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04573023
Een fase III-studie van JR-141 bij patiënten met mucopolysaccharidose II
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Buenos Aires, Argentinië
- Hospital Universitario Austral
-
-
-
-
-
Porto Alegre, Brazilië
- Hospital de Clínicas de Porto Alegre
-
São Paulo, Brazilië
- Instituto de Genética e Erros Inatos do Metabolismo
-
-
-
-
-
Bogotá, Colombia
- Fundación Cardio Infantil - Instituto de Cardiología
-
-
-
-
-
Giessen, Duitsland
- Universitätsklinikum Giessen
-
Hamburg, Duitsland
- Universitätsklinikum Hamburg-Eppendorf
-
Höchheim, Duitsland
- SphinCS GmbH
-
Mainz, Duitsland
- Universitätsmedizin Mainz
-
-
-
-
-
Lyon, Frankrijk
- Hôpital Femme Mère Enfant
-
Montpellier, Frankrijk
- Chu De Montpellier Hopital Gui De Chauliac
-
Paris, Frankrijk
- Hôpital Armand Trousseau
-
-
-
-
-
Afula, Israël, 1834111
- Clalit Health Services Ha'Emek Medical Center
-
Ramat Gan, Israël, 6265601
- Sheba Medical Center
-
-
-
-
-
Rome, Italië
- Osp. Pediatrico Bambino Gesù, IRCCS
-
-
-
-
-
Krakow, Polen
- Uniwersytecki Szpital Dziecięcy
-
-
-
-
-
Barcelona, Spanje
- Hospital Sant Joan de Déu
-
-
-
-
-
Ankara, Turkije (Türkiye)
- Gazi University Medicine Faculty Hospital
-
Izmir, Turkije (Türkiye)
- Ege University Children Hospital
-
-
-
-
-
London, Verenigd Koninkrijk
- Great Ormond Street Hospital for Children NHS Trust - Metabolic Medicine
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85016
- Phoenix Children's Hospital
-
-
California
-
Oakland, California, Verenigde Staten, 94609
- UCSF Benioff Children's Hospital Oakland
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- University of Minnesota
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Columbia University Irving Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27514
- University of North Carolina at Chapel Hill Medical School Wing E
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Children's Hospital of Philadelphia
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- A patient who voluntarily signs an Institutional Review Board or Independent Ethics Committee-approved written informed consent form. If the patient is aged under 18 years (aged under 16 years in the UK) at the time of enrollment or willingness to participate in the study cannot be confirmed due to MPS II-related intellectual disability, the patient's legally acceptable representative (e.g., his/her parents or guardians) may sign the informed consent on behalf of the patient. Written informed assent should be obtained from the patient, wherever possible.
- Patients with confirmed diagnosis of MPS II
- Naïve patients or patients who are receiving stable enzyme replacement therapy with idursulfase for more than 12 weeks before starting administration of JR-141 or idursulfase for this study.
- Patients or patients whose partners are of child-bearing potential agree to use a medically accepted, highly effective method of contraception being use of condoms from the time of informed consent.
<Cohort A>
- Patients aged 36-42 months old at the time of ICF signing: patients must have a standard score measured by the BSID-III of 85 or less at screening.
- Patients aged 43-71 months old at the time of ICF signing: patients must EITHER have (1) A DQ measured by BSID-III of 20 to 85 at screening OR (2) A composite standard score on NVI measured by KABC-II of 85 or less at screening (only who can perform KABC-II)
- Patients aged 30-35 months old at the time of randomization and who are judged as having the severe phenotype by the Expert Board.
<Cohort B>
- Patients 6 years of age or older at the time of ICF signing and whose IQ are 70 and higher.
- Enrollment of subjects in Cohort B is contingent on the availability in that country of a validated country-specific version of the test (either WISC-V, WAIS-IV, or T.O.V.A.).
- Attenuated patients with 1 SD deficiency in the omission errors or variability domains of the T.O.V.A..
- Patients or patients whose female partners are of child-bearing potential i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile, agree to use a medically accepted, highly effective method of contraception, from the time of informed consent. The method of contraception must be used during the study until 90 days for male subjects, and 30 days for female subjects after the final study intervention administration.
- For subjects with hearing impairment requiring hearing aid(s), every effort has been made to encourage compliance with the use of functioning hearing aid(s) before baseline neurocognitive assessments, and parent/legally acceptable representative or subject agrees to encourage wearing them during the study and on neurocognitive testing days.
Exclusion Criteria:
- A patient with a history of HSCT with successful engraftment.
- A patient who has received gene therapy treatment at any point.
- A patient who is judged by the principal investigator or sub-investigator as being unable to undergo lumbar puncture, including those who have difficulties in taking position for lumbar puncture due to joint contracture or those who are likely to experience breathing difficulties during the lumbar puncture process.
- A patient who is enrolled in another clinical study that involves clinical investigations or use of any investigational product (drug or device) within 4 months before obtaining informed consent.
- Unable to comply with the protocol as determined by the principal investigator or subinvestigator.
- Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of serious drug allergy or sensitivity including anesthesia or hypersensitivity to any component of JR-141.
- A patient who has a known or suspected local or general infection or is at risk of abnormal bleeding due to medical conditions or therapies.
- A patient who has documented mutation of other genes, including loci adjacent to the IDS gene that are known to be associated with developmental delay, seizures, or other significant CNS disorders.
- A patient who has documented loss of activity of sulfatases other than IDS.
- A patient who has had a ventriculoperitoneal shunt placed or any other brain surgery, or has a clinically significant ventriculoperitoneal shunt malfunction within 30 days of screening.
- A patient who is full time employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members.
- A patient who otherwise is judged by the principle investigator or sub-investigator to be ineligible to participate in the study.
- The subject has a positive pregnancy test or is breastfeeding at screening or randomization.
[Only in France]
- Persons deprived of their liberty by a judicial or administrative decision, according to article L.1121-6 the Public Health Code (Code de la santé publique), adults who are the subject of a measure of legal protection or unable to express their consent according to article L. 1121-8 of the Code de la santé publique)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: JR-141 2,0 mg/kg/week
|
IV infusion, 2.0 mg/kg/week |
|
Ander: Reddingsarm
|
The subjects who have achieved the pre-specified criteria* are able to change the drug. *If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141. If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase. |
|
Ander: administered as the standard of care: idursulfase (ELAPRASE®)
standard of care-controlled study |
IV infusion |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Verandering in niveaus van cerebrospinale vloeistof heparansulfaat vanaf baseline (cohort A)
Tijdsspanne: Basislijn tot week 53
|
Basislijn tot week 53
|
|
Verandering in de ruwe scores van cognitieve testen gemeten vanaf baseline (BSID-III) (Cohort A)
Tijdsspanne: Basislijn tot week 105
|
Basislijn tot week 105
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Voor andere regio's dan wij: verandering in de leeftijdsequivalent scores van cognitieve testen gemeten uit baseline (BSID-III of KABC-II) (cohort A)
Tijdsspanne: Baseline naar week 105
|
Baseline naar week 105
|
|
Voor andere regio's dan wij: verandering in de leeftijdsequivalent scores van adaptief gedrag gemeten uit baseline (VABS-II) (cohort A)
Tijdsspanne: Baseline naar week 105
|
Baseline naar week 105
|
|
Voor de VS: verandering in de ruwe scores van adaptief gedrag gemeten uit baseline (VABS-II) (cohort A)
Tijdsspanne: Baseline naar week 105
|
Baseline naar week 105
|
|
Voor alle regio's: relatieve verandering in levervolume ten opzichte van lichaamsgewicht van de basislijn (cohort A en cohort B)
Tijdsspanne: Baseline naar week 53
|
Baseline naar week 53
|
|
Voor alle regio's: relatieve verandering in miltvolume ten opzichte van lichaamsgewicht van de basislijn (cohort A en cohort B)
Tijdsspanne: Baseline naar week 53
|
Baseline naar week 53
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Ziekten van het zenuwstelsel
- Metabolisme, aangeboren fouten
- Genetische ziekten, aangeboren
- Metabole ziekten
- Bindweefselziekten
- Neurologische gedragsmanifestaties
- Heredodegeneratieve aandoeningen, zenuwstelsel
- Verstandelijk gehandicapt
- Genetische ziekten, X-gekoppeld
- Koolhydraatmetabolisme, aangeboren fouten
- Lysosomale stapelingsziekten
- Mucinosen
- Mucopolysaccharidosen
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Voedings- en stofwisselingsziekten
- Huid- en bindweefselaandoeningen
- X-gebonden intellectuele handicap
- Mucopolysaccharidose II
- idursulfase
Andere studie-ID-nummers
- JR-141-GS31
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .